Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Theratechnologies Inc > Assumption
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
Comment by Thao977on Dec 06, 2021 10:08am
75 Views
Post# 34201840

RE:Assumption

RE:AssumptionIt was normally february according to SEDI 

Transaction ID Date of transaction
YYYY-MM-DD		 Date of filing
YYYY-MM-DD		 Ownership type (and registered holder, if applicable) Nature of transaction Number or value acquired or disposed of Unit price or exercise price Closing balance Insider's calculated balance Conversion
or exercise
price		 Date of expiry or maturity
YYYY-MM-DD		 Underlying security designation Equivalent number or value of underlying securities acquired or disposed of Closing balance of equivalent number or value of underlying securities  
Insider name: Antunovic, Jovan  
Insider's Relationship to Issuer: 5 - Senior Officer of Issuer  
Ceased to be Insider: 2020-11-13  
Security designation: Options (Common Shares)  
        3502981 2020-02-26 2020-02-26 Direct Ownership : 50 - Grant of options +50,000 3.2200   83,000       2030-02-26 Common Shares +50,000 83,000  
   
Insider name: Arena, Joseph  
Insider's Relationship to Issuer: 4 - Director of Issuer  
Ceased to be Insider: Not applicable  
Security designation: Options (Common Shares)  
        3840503 2021-05-15 2021-12-02 Direct Ownership : 00 - Opening Balance-Initial SEDI Report                 Common Shares      
   
        3840599 2021-12-01 2021-12-02 Direct Ownership : 50 - Grant of options +14,170     14,170   3.3000 USD 2031-12-01 Common Shares +14,170 14,170  
   
Insider name: Boucher, Denis  
Insider's Relationship to Issuer: 5 - Senior Officer of Issuer  
Ceased to be Insider: Not applicable  
Security designation: Options (Common Shares)  
        3502928 2020-02-26 2020-02-26 Direct Ownership : 50 - Grant of options +27,900 3.2200   68,122       2030-02-26 Common Shares 0 40,222  
   
        3691779 2021-02-26 2021-03-03 Direct Ownership : 50 - Grant of options +43,161 3.9300   111,283       2031-02-26 Common Shares 0 40,222  
   
Insider name: Colussi, Marie-Nol  
Insider's Relationship to Issuer: 5 - Senior Officer of Issuer  
Ceased to be Insider: Not applicable  
Security designation: Options (Common Shares)  
        3508848 2020-02-26 2020-03-04 Direct Ownership : 50 - Grant of options +27,900 3.2200   125,193   3.2200   2030-02-26 Common Shares +27,900 125,193  
   
        3541860 2020-04-23 2020-04-24 Direct Ownership : 51 - Exercise of options -20,000 3.8400   105,193   3.8400   2020-04-23 Common Shares -20,000 105,193  
   
        3691927 2021-02-26 2021-03-03 Direct Ownership : 50 - Grant of options +54,087 3.9300   159,280   3.9300   2031-02-26 Common Shares +54,087 159,280  
   
        3841716 2021-12-01 2021-12-03 Direct Ownership : 50 - Grant of options +78,812 4.2100   238,092       2031-12-01 Common Shares +78,812 238,092  
   
Insider name: Dubuc, Philippe  
Insider's Relationship to Issuer: 5 - Senior Officer of Issuer  
Ceased to be Insider: Not applicable  
Security designation: Options (Common Shares)  
        3503907 2020-02-26 2020-02-27 Direct Ownership : 50 - Grant of options +50,000 3.2200   327,286       2030-02-26 Common Shares +50,000 327,286  
   
        3690960 2021-02-26 2021-03-02 Direct Ownership : 50 - Grant of options +73,233 3.9300   400,519       2031-02-26 Common Shares +73,233 400,519  
   
        3841686 2021-12-01 2021-12-03 Direct Ownership : 50 - Grant of options +157,895 4.2100   558,414       2031-12-01 Common Shares +157,895 558,414  
   
Insider name: Dupras, Andre  
Insider's Relationship to Issuer: 5 - Senior Officer of Issuer  
Ceased to be Insider: Not applicable  
Security designation: Options (Common Shares)  
        3840824 2021-05-31 2021-12-02 Direct Ownership : 00 - Opening Balance-Initial SEDI Report                 Common Shares      
   
        3841217 2021-12-01 2021-12-03 Direct Ownership : 50 - Grant of options +141,404 4.2100   141,404       2031-12-01 Common Shares +141,404 141,404  
   
Insider name: Frame, Sheila  
Insider's Relationship to Issuer: 4 - Director of Issuer  
Ceased to be Insider: Not applicable  
Security designation: Options (Common Shares)  
        3502961 2020-02-26 2020-02-26 Direct Ownership : 50 - Grant of options +10,600 3.2200   10,600 10,600     2030-02-26 Common Shares 0 0  
   
        3691360 2021-02-26 2021-03-02 Direct Ownership : 50 - Grant of options +13,258 3.9300   23,858       2031-02-26 Common Shares +13,258 13,258  
   
Insider name: Holler, Frank  
Insider's Relationship to Issuer: 4 - Director of Issuer  
Ceased to be Insider: Not applicable  
Security designation: Options (Common Shares)  
        3841931 2021-06-23 2021-12-03 Direct Ownership : 00 - Opening Balance-Initial SEDI Report                 Common Shares      
   
        3841939 2021-12-01 2021-12-03 Direct Ownership : 50 - Grant of options +14,170 4.2100   14,170       2031-12-01 Common Shares +14,170 14,170  
   
Insider name: Lacoste, Grald A.  
Insider's Relationship to Issuer: 4 - Director of Issuer  
Ceased to be Insider: Not applicable  
Security designation: Options (Common Shares)  
        3503866 2020-02-26 2020-02-27 Direct Ownership : 50 - Grant of options +10,600     66,746 66,746 3.2200   2030-02-26 Common Shares +10,600 66,746  
   
        3688775 2020-11-27 2021-02-28 Direct Ownership : 52 - Expiration of options -10,000 4.7500   56,746   4.7500   2020-06-08 Common Shares -10,000 56,746  
   
        3688776 2021-02-26 2021-02-28 Direct Ownership : 50 - Grant of options +13,258 3.9300   70,004 70,004 3.9300   2031-02-26 Common Shares +13,258 70,004  
   
        3842225 2021-12-01 2021-12-04 Direct Ownership : 50 - Grant of options +14,170 4.2100   84,174 84,174     2031-12-01 Common Shares +14,170 84,174  
   
Insider name: Lafond, Jocelyn  
Insider's Relationship to Issuer: 5 - Senior Officer of Issuer  
Ceased to be Insider: Not applicable  
Security designation: Options (Common Shares)  
        3502958 2020-02-26 2020-02-26 Direct Ownership : 50 - Grant of options +27,900 3.2200   260,193       2030-02-26 Common Shares 0 232,293  
   
        3691462 2021-02-26 2021-03-02 Direct Ownership : 50 - Grant of options +63,260 3.9300   323,453       2031-02-26 Common Shares +63,260 295,553  
   
        3841224 2021-12-01 2021-12-03 Direct Ownership : 50 - Grant of options +111,404 4.2100   434,857       2031-12-01 Common Shares +111,404 406,957  
   
Insider name: Leasure, John  
Insider's Relationship to Issuer: 5 - Senior Officer of Issuer  
Ceased to be Insider: Not applicable  
Security designation: Options (Common Shares)  
        3782699 2021-03-29 2021-07-30 Direct Ownership : 00 - Opening Balance-Initial SEDI Report                 Common Shares      
   
        3782702 2021-07-27 2021-07-30 Direct Ownership : 50 - Grant of options +21,515 3.4800 USD 21,515       2031-07-27 Common Shares +21,515 21,515  
   
        3842283 2021-12-01 2021-12-05 Direct Ownership : 50 - Grant of options +133,333 3.3000 USD 154,848       2031-12-01 Common Shares +133,333 154,848  
   
Insider name: Lvesque, Paul  
Insider's Relationship to Issuer: 5 - Senior Officer of Issuer  
Ceased to be Insider: Not applicable  
Security designation: Options (Common Shares)  
        3539432 2020-04-06 2020-04-16 Direct Ownership : 00 - Opening Balance-Initial SEDI Report                 Common Shares      
   
    O   3539433 2020-04-15 2020-04-16 Direct Ownership : 50 - Grant of options +487,421 2.8700     487,421     2030-04-15 Common Shares 0    
   
    A   3539433 2020-04-15 2020-04-20 Direct Ownership : 50 - Grant of options +487,421 2.8700   487,421 487,421     2030-04-15 Common Shares +487,421 487,421  
   
        3691302 2021-02-26 2021-03-02 Direct Ownership : 50 - Grant of options +243,307 3.9300   730,728 730,728     2031-02-26 Common Shares +243,307 730,728  
   
        3841230 2021-12-01 2021-12-03 Direct Ownership : 50 - Grant of options +404,000 4.2100   1,134,728       2031-12-01 Common Shares +404,000 1,134,728  
   
Insider name: Littlejohn, Gary Peter  
Insider's Relationship to Issuer: 4 - Director of Issuer  
Ceased to be Insider: Not applicable  
Security designation: Options (Common Shares)  
        3504201 2020-02-26 2020-02-27 Direct Ownership : 50 - Grant of options +10,600 3.2200   19,500   3.2200   2030-02-26 Common Shares +35,000 43,900  
   
    O   3688517 2021-02-26 2021-02-28 Direct Ownership : 50 - Grant of options +13,258 4.0900           2031-02-26 Common Shares +35,000    
   
    A   3688517 2021-02-26 2021-02-28 Direct Ownership : 50 - Grant of options +13,258 3.9300   32,758       2031-02-26 Common Shares +35,000 78,900  
   
        3842284 2021-12-01 2021-12-05 Direct Ownership : 50 - Grant of options +14,170 4.2100   46,928   4.2100   2031-12-01 Common Shares +35,000 113,900  
   
Insider name: Marsolais, Christian  
Insider's Relationship to Issuer: 5 - Senior Officer of Issuer  
Ceased to be Insider: Not applicable  
Security designation: Options (Common Shares)  
        3503901 2020-02-26 2020-02-27 Direct Ownership : 50 - Grant of options +50,000 3.2200   362,286       2030-02-26 Common Shares +50,000 362,286  
   
        3503902 2020-02-26 2020-02-27 Direct Ownership : 50 - Grant of options +100,000 3.2200   462,286       2030-02-26 Common Shares +100,000 462,286  
   
        3674317 2020-04-23 2021-02-05 Direct Ownership : 52 - Expiration of options -35,000     427,286       2020-04-23 Common Shares -35,000 427,286  
   
        3690103 2021-02-26 2021-03-02 Direct Ownership : 50 - Grant of options +95,192 3.9300   522,478       2031-02-26 Common Shares +95,192 522,478  
   
        3842246 2021-12-01 2021-12-05 Direct Ownership : 50 - Grant of options +157,895 4.2100   680,373       2031-12-01 Common Shares +157,895 680,373  
   
Insider name: Molson, Andrew  
Insider's Relationship to Issuer: 4 - Director of Issuer  
Ceased to be Insider: Not applicable  
Security designation: Options (Common Shares)  
        3691329 2020-10-16 2021-03-02 Direct Ownership : 00 - Opening Balance-Initial SEDI Report                 Common Shares      
   
        3691333 2021-02-26 2021-03-02 Direct Ownership : 50 - Grant of options +13,258 3.9300   13,258 13,258     2031-02-26 Common Shares +13,258 13,258  
   
        3840783 2021-12-01 2021-12-02 Direct Ownership : 50 - Grant of options +14,170 4.2100   27,428       2031-12-01 Common Shares +14,170 27,428  
   
Insider name: Pommier, Paul  
Insider's Relationship to Issuer: 4 - Director of Issuer  
Ceased to be Insider: Not applicable  
Security designation: Options (Common Shares)  
        3502965 2020-02-26 2020-02-26 Direct Ownership : 50 - Grant of options +10,600 3.2200   66,746       2030-02-26 Common Shares 0 56,146  
   
        3691326 2021-02-26 2021-03-02 Direct Ownership : 50 - Grant of options +13,258 3.9300   80,004       2031-02-26 Common Shares +13,258 69,404  
   
Insider name: Svoronos, Dawn  
Insider's Relationship to Issuer: 4 - Director of Issuer  
Ceased to be Insider: Not applicable  
Security designation: Options (Common Shares)  
        3502967 2020-02-26 2020-02-26 Direct Ownership : 50 - Grant of options +10,600 3.2200   106,746       2030-02-26 Common Shares 0 96,146  
   
        3691325 2021-02-26 2021-03-02 Direct Ownership : 50 - Grant of options +13,258 3.9300   120,004       2031-02-26 Common Shares +13,258 109,404  
   
        3840778 2021-12-01 2021-12-02 Direct Ownership : 50 - Grant of options +14,170 4.2100   134,174       2031-12-01 Common Shares +14,170 123,574  
   
Insider name: TRUDEAU, ALAIN  
Insider's Relationship to Issuer: 4 - Director of Issuer  
Ceased to be Insider: Not applicable  
Security designation: Options (Common Shares)  
        3688917 2020-10-16 2021-03-01 Direct Ownership : 00 - Opening Balance-Initial SEDI Report                 Common Shares      
   
    O   3688927 2021-02-26 2021-03-01 Direct Ownership : 11 - Acquisition or disposition carried out privately +13,258 3.9300           2031-02-26 Common Shares +13,258    
   
    A   3688927 2021-02-26 2021-12-02 Direct Ownership : 50 - Grant of options +13,258 3.9300   13,258       2031-02-26 Common Shares +13,258 13,258  
   
    O   3840580 2021-12-01 2021-12-02 Direct Ownership : 50 - Grant of options +14,170 4.2100       4.2100   2031-12-01 Common Shares +14,170    
   
    A   3840580 2021-12-01 2021-12-02 Direct Ownership : 50 - Grant of options +14,170 4.2100   27,428       2031-12-01 Common Shares +14,170 27,428  
   
Insider name: Walshe, Conor  
Insider's Relationship to Issuer: 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)  
Ceased to be Insider: Not applicable  
Security designation: Options (Common Shares)  
        3503803 2020-02-26 2020-02-27 Direct Ownership : 50 - Grant of options +40,000 3.2200   90,000       2023-02-26 Common Shares 0 50,000  
   
        3691739 2021-02-26 2021-03-03 Direct Ownership : 50 - Grant of options +63,333 3.9300   153,333       2031-02-26 Common Shares +63,333 113,333  
   
        3842215 2021-12-04 2021-12-04 Direct Ownership : 50 - Grant of options +70,000 4.2100   223,333       2031-12-01 Common Shares +70,000 183,333  
   
Insider name: Weil, Dale  
Insider's Relationship to Issuer: 4 - Director of Issuer  
Ceased to be Insider: Not applicable  
Security designation: Options (Common Shares)  
        3502970 2020-02-26 2020-02-26 Direct Ownership : 50 - Grant of options +10,600 3.2200   41,746       2030-02-26 Common Shares 0 31,146  
   
    O   3687850 2021-02-25 2021-02-26 Direct Ownership : 50 - Grant of options +35,000 2.6400       2.6400   2031-02-26 Common Shares +13,258    
   
    A   3687850 2021-02-25 2021-02-28 Direct Ownership : 50 - Grant of options +35,000 2.6400       3.9300   2031-02-26 Common Shares +13,258    
   
    A ' 3687850 2021-02-26 2021-03-02 Direct Ownership : 50 - Grant of options +13,258 3.9300   55,004       2031-02-26 Common Shares +13,258 44,404  
   

        3842224 2021-12-01 2021-12-04 Direct Ownership : 50 - Grant of options +14,170 4.2100   69,174       2031-12-01 Common Shares +14,170 58,574

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities